Sign In  |  Register  |  About Livermore  |  Contact Us

Livermore, CA
September 01, 2020 1:25pm
7-Day Forecast | Traffic

  • Search Hotels in Livermore

  • CHECK-IN:
  • CHECK-OUT:
  • ROOMS:
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Bioatla Inc (NQ: BCAB )

1.390 -0.090 (-6.08%)
Streaming Delayed Price Updated: 4:00 PM EST, Nov 21, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 1,970,966
Open 1.450
Bid (Size) 1.350 (1)
Ask (Size) 1.480 (8)
Prev. Close 1.480
Today's Range 1.330 - 1.500
52wk Range 1.140 - 4.020
Shares Outstanding N/A
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
'Big Short' Investor Michael Burry's China Bet Pays Off As Top Picks Surge Nearly 60% In 2 Months
Michael Burry, the investor renowned for his prescient bet against the housing market before the 2008 financial crisis, has seen his recent wager on Chinese stocks pay significant dividends. 
Via Benzinga
12 Health Care Stocks Moving In Wednesday's Intraday Session
Via Benzinga

Performance

YTD
-47.55%
-47.55%
1 Month
-28.72%
-28.72%
3 Month
-26.46%
-26.46%
6 Month
-39.04%
-39.04%
1 Year
-13.13%
-13.13%

More News

Read More
BioAtla and Context Therapeutics Announce Exclusive Worldwide License Agreement to Develop and Commercialize BA3362, a Nectin-4 x CD3 T Cell Engaging Antibody
From Context Therapeutics Inc.
Via GlobeNewswire
'Big Short' Fame Michael Burry Bets Big On China, Reveals Alibaba As Top Holding — JD.com And Baidu Also Feature On Scion's Portfolio
Via Benzinga
BCAB Stock Earnings: BioAtla Meets EPS for Q2 2024
Via InvestorPlace
BCAB Stock Earnings: BioAtla Beats EPS for Q1 2024
Via InvestorPlace
12 Health Care Stocks Moving In Tuesday's After-Market Session
Via Benzinga
12 Health Care Stocks Moving In Thursday's Intraday Session
Via Benzinga
BCAB Stock Earnings: BioAtla Beats EPS for Q4 2023
Via InvestorPlace
BioAtla: Q4 Earnings Insights
Via Benzinga
Preview: BioAtla's Earnings
Via Benzinga
Analyst Ratings for BioAtla
Via Benzinga
Earnings Scheduled For March 26, 2024
Via Benzinga
Around $2M Bet On This Healthcare Stock? Check Out These 4 Penny Stocks Insiders Are Aggressively Buying
Via Benzinga
Topics Stocks
Exposures US Equities
BioAtla to Participate in the 42nd Annual J.P. Morgan Healthcare Conference
From BioAtla, Inc.
Via GlobeNewswire
12 Health Care Stocks Moving In Monday's After-Market Session
Via Benzinga
BioAtla Presented Phase 2 Clinical Trial Data at the IASLC 2023 North America Conference on Lung Cancer and Virtual KOL Event
From BioAtla, Inc.
Via GlobeNewswire
12 Health Care Stocks Moving In Monday's Intraday Session
Via Benzinga
BioAtla to Participate in the JMP Securities Hematology and Oncology Summit
From BioAtla, Inc.
Via GlobeNewswire
BioAtla to Host Virtual KOL Event to Review IASLC Data on BA3011 in NSCLC
From BioAtla, Inc.
Via GlobeNewswire
BioAtla Reports Third Quarter 2023 Financial Results and Highlights Recent Progress
From BioAtla, Inc.
Via GlobeNewswire
BioAtla to Participate in the Jefferies London Healthcare Conference
From BioAtla, Inc.
Via GlobeNewswire
BioAtla’s Jay M. Short, Ph.D., Selected for The Explorers Club Lowell Thomas Award
From BioAtla, Inc.
Via GlobeNewswire
BioAtla Provides Guidance on Near-Term Milestones and Plans to Announce Third Quarter 2023 Financial Results and Business Update on November 7, 2023
From BioAtla, Inc.
Via GlobeNewswire
BioAtla to Participate in the H.C. Wainwright 25th Annual Global Investment Conference
From BioAtla, Inc.
Via GlobeNewswire
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
 
 
About Us | Contact Us | Privacy Policy | User Agreement | Advertise With Us | Site Map
Copyright © 2010-2020 Livermore.com & California Media Partners, LLC. All rights reserved.